Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Addex Therapeutics Ltd

Healthcare US ADXN

6.4USD
-0.25(3.76%)

Last update at 2026-06-02T20:00:00Z

Day Range

6.406.63
LowHigh

52 Week Range

5.4112.05
LowHigh

Fundamentals

  • Previous Close 6.65
  • Market Cap8.66M
  • Volume957
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.45684M
  • Revenue TTM0.16M
  • Revenue Per Share TTM0.24
  • Gross Profit TTM -0.52565M
  • Diluted EPS TTM-9.18

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -4.90934M -2.50015M -20.80421M -15.35191M -12.85860M
Minority interest - - - - -
Net income 7.06M -10.55623M -21.06857M -15.41493M -12.92810M
Selling general administrative 1.68M 2.03M 7.30M 5.14M 5.15M
Selling and marketing expenses - 2.21M - - -
Gross profit 0.40M 1.61M 1.42M 2.92M 3.61M
Reconciled depreciation 0.26M 0.31M 0.32M 0.35M 0.38M
Ebit -4.90580M -2.49629M -20.52021M -15.50592M -12.24327M
Ebitda -4.64567M -2.19034M -20.16781M -15.15298M -11.82921M
Depreciation and amortization 0.26M 0.31M 0.35M 0.35M 0.41M
Non operating income net other - - - - -
Operating income -2.75523M -2.24297M -20.52021M -15.50592M -12.24327M
Other operating expenses 3.16M 3.86M 21.94M 18.42M 15.86M
Interest expense 0.00355M 0.02M 0.05M 0.06M 0.07M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.00916M 0.06M 0.03M 0.00532M 0.04M
Net interest income 0.00562M 0.04M -0.01965M -0.05769M -0.03420M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.02M 0.26M 0.06M 0.07M
Total revenue 0.40M 1.61M 1.42M 2.92M 3.61M
Total operating expenses 3.16M 3.86M 21.94M 18.42M 15.86M
Cost of revenue 0.85M 6.94M - - -
Total other income expense net -2.15411M -0.25719M -0.28401M 0.15M -0.61533M
Discontinued operations - - - - -
Net income from continuing ops -4.90934M -10.55623M -20.80421M -15.35191M -12.85860M
Net income applicable to common shares - - -20.80421M -15.35191M -12.85860M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 10.68M 4.64M 8.28M 22.54M 20.18M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.18M 0.22M 871.88M 1.12M 0.66M
Total liab 1.00M 3.50M 3.37M 5.61M 5.57M
Total stockholder equity 9.68M 1.15M 4.91M 16.93M 14.61M
Deferred long term liab - - - - -
Other current liab 0.52M 1.40M 1.72M 2.06M 1.51M
Common stock 1.84M 1.84M 1.15M 49.27M 32.85M
Capital stock 1.84M 1.84M 1.15M 49.27M 32.85M
Retained earnings -353.36246M -360.41824M -349.86201M -329.05780M -313.70589M
Other liab - - - 1.28M 1.69M
Good will - - - - -
Other assets - - 0.05M 0.06M 0.06M
Cash 3.34M 3.87M 6.96M 20.48M 18.70M
Cash and equivalents - - - - -
Total current liabilities 0.80M 2.89M 3.28M 4.13M 3.62M
Current deferred revenue - 0.23M - - 0.82M
Net debt -3.29974M -3.52115M -6.58395M -20.00282M -18.12764M
Short term debt 0.00731M 0.27M 0.29M 0.29M 0.31M
Short long term debt - - - - -
Short long term debt total 0.04M 0.34M 0.37M 0.48M 0.57M
Other stockholder equity 330.13M 329.91M 327.85M 272.28M 286.89M
Property plant equipment - - 0.40M 0.54M 0.63M
Total current assets 3.54M 4.23M 7.83M 21.94M 19.49M
Long term investments 7.09M - - - -
Net tangible assets - - 4.91M 16.93M 14.61M
Short term investments 0.00650M 0.00085M 0.00316M 0.02M 0.06M
Net receivables 0.02M 0.15M 0.60M 0.32M 0.07M
Long term debt - - - - -
Inventory - - -871.60461M - -
Accounts payable 0.25M 0.98M 1.28M 1.79M 0.98M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 31.06M 29.81M 25.77M 24.44M 8.58M
Additional paid in capital - - - - -
Common stock total equity - - - - 32.85M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00709M 0.05M 0.05M 0.06M 0.06M
Deferred long term asset charges - - - - -
Non current assets total 7.14M 0.41M 0.45M 0.60M 0.69M
Capital lease obligations 0.04M 0.34M 0.37M 0.48M 0.57M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 4.65M -0.00684M 0.00297M 0.00124M -0.05941M
Change to liabilities - - -0.42739M 0.06M -2.04192M
Total cashflows from investing activities 4.65M -0.00684M 0.00297M -0.03031M -0.05941M
Net borrowings -0.07369M -0.28179M -0.28808M -0.30962M -0.36741M
Total cash from financing activities 0.10M 5.26M 3.10M 16.40M 0.05M
Change to operating activities - - 0.86M -0.56921M 0.17M
Net income 7.06M -10.55623M -20.80421M -15.35191M -12.85860M
Change in cash -0.52374M -3.09160M -13.52775M 1.79M -12.84176M
Begin period cash flow 3.87M 6.96M 20.48M 18.70M 31.54M
End period cash flow 3.34M 3.87M 6.96M 20.48M 18.70M
Total cash from operating activities -5.37355M -7.99241M -16.43718M -14.70519M -12.18007M
Issuance of capital stock 0.24M 2.35M 1.68M 13.96M 0.72M
Depreciation 0.26M 0.31M 0.32M 0.35M 0.38M
Other cashflows from investing activities 5.12M - - - -
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change to inventory - 0.61M - - -
Change to account receivables 0.13M 0.31M -0.25209M -0.09641M 0.05M
Sale purchase of stock -0.00176M -0.04805M - - -
Other cashflows from financing activities -0.06229M 3.20M 1.71M 2.75M -0.30620M
Change to netincome - - 3.89M 1.06M 2.12M
Capital expenditures 0.00127M 0.00684M 0.00058M 0.03M 0.06M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.22837M 0.21M 0.16M -0.76157M -1.82154M
Stock based compensation - 1.79M 3.68M 1.18M 1.18M
Other non cash items -11.46109M 0.25M 0.20M 0.03M 0.97M
Free cash flow -5.37483M -7.99925M -16.43777M -14.73673M -12.23948M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ADXN
Addex Therapeutics Ltd		 -0.25 3.76% 6.40 - - 54.63 1.12 136.36 -0.757
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Addex Therapeutics Ltd

Chemin des Mines, 9, Geneva, Switzerland, 1202

Key Executives

Name Title Year Born
Mr. Timothy Mark Dyer Co-Founder, CEO & Director 1968
Dr. Roger G. Mills M.D. Chief Medical Officer & Director 1957
Mr. Lénaic Teyssédou Head of Fin. 1986
Dr. Jean-Philippe Rocher Ph.D. Head of Discovery - Chemistry 1959
Dr. Robert Lutjens Head of Discovery - Biology 1968
Dr. Mikhail Kalinichev Ph.D. Head of Translational Science 1968
Dr. Werner Henrichi Ph.D. Consultant 1943
Mr. Lénaic Teyssédou Head of Finance 1986
Dr. Mikhail Kalinichev Ph.D. Head of Translational Science 1967

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.